Biogen to Initiate Phase 4 Study Evaluating Benefit of Spinraza® in Patients Treated With Zolgensma®
21 July 2020
Biogen have announced today that it plans to initiate a global Phase 4 clinical study, called RESPOND, to examine the clinical benefit, and assess the safety, of Spinraza®
(nusinersen) in infants and children who have SMA, who still have unmet clinical needs following treatment with the gene therapy treatment Zolgensma® (onasemnogene abeparvovec).
The study is projected to enroll 60 children up to age 3 who are determined by the investigator to have the potential for additional clinical improvement after receiving Zolgensma®.
Biogen have provided an update to the Community about this with further information: